<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01087710</url>
  </required_header>
  <id_info>
    <org_study_id>AK22</org_study_id>
    <nct_id>NCT01087710</nct_id>
  </id_info>
  <brief_title>Effect of Medical Food on Reducing Asthma Symptoms in Asthmatic Children</brief_title>
  <official_title>Effect of Novel Medical Food on Reducing the Frequency and Severity of Asthma Symptoms and Airway Hyper-responsiveness in Children With Mild to Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of medical food on reducing asthma symptoms in asthmatic children.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>asthma free days</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of airway hyper-responsiveness</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to the first asthma exacerbation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory function (spirometry)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for rescue for exacerbations of asthma symptoms.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>novel nutritional formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control nutritional product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 8oz serving per day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical food with EPA and GLA, vitamins and minerals</intervention_name>
    <description>1 8oz serving per day for 12 weeks</description>
    <arm_group_label>novel nutritional formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical food minus EPA and GLA, antioxidant vitamins/minerals</intervention_name>
    <description>1 8oz serving a day for 12 weeks</description>
    <arm_group_label>Control nutritional product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female children who have had mild to moderate persistent asthma for at least&#xD;
             1 year and are between 6 and 14 years of age, and not currently being treated with&#xD;
             steroids are eligible.&#xD;
&#xD;
        Each subject also has to have:&#xD;
&#xD;
          -  Subject is off of controller therapy 4 wks preceding visit 1.&#xD;
&#xD;
          -  Mild to moderate persistent asthma&#xD;
&#xD;
          -  Methacholine responsiveness with an FEV1 PC20&#xD;
&#xD;
          -  Able to perform reproducible spirometry&#xD;
&#xD;
          -  Verbal assent in addition to consent&#xD;
&#xD;
          -  History of prior clinical varicella or varicella vaccine.&#xD;
&#xD;
          -  Nonsmoker in past year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Asthma symptoms and/or albuterol use consistent with severe persistent asthma during&#xD;
             the run-in period.&#xD;
&#xD;
          -  Subject with FEV1 &lt; 80% predicted at visit 1 or FEV1 &lt; 70% predicted at visit 2.&#xD;
&#xD;
          -  Two or more hospitalizations for asthma in the past year.&#xD;
&#xD;
          -  Subject has received oral, nasal, inhaled, or IM corticosteroids during the preceding&#xD;
             month.&#xD;
&#xD;
          -  Subject has received leukotriene modifiers, theophylline derivatives, or mast cell&#xD;
             stabilizers for asthma within 4 weeks before visit 1&#xD;
&#xD;
          -  Subject is receiving one or more of the following medications:&#xD;
&#xD;
               -  Astemizole prior to 3 months of visit 1&#xD;
&#xD;
               -  Oral, inhaled or parenteral corticosteroids prior to 4 weeks of visit 1&#xD;
&#xD;
               -  Cromolyn, antimuscarinics, cimetidine, metoclopramide, phenobarbital, phenytion,&#xD;
                  terfenadine, loratadine, or anticholingeric agents prior to 2 weeks of visit 1.&#xD;
&#xD;
               -  Theophylline prior to 4 weeks of visit 1&#xD;
&#xD;
          -  Subject with active upper respiratory tract infection prior to 4 weeks before visit 1&#xD;
&#xD;
          -  Subject with acute sinus disease requiring antibiotic treatment within 1 week before&#xD;
             visit&#xD;
&#xD;
          -  Subject with an emergency department treatment for asthma within 1 month, prior&#xD;
             intubation for asthma, or hospitalization for asthma within 3 months&#xD;
&#xD;
          -  Subject has known bleeding disorder and/or is on medication known to have significant&#xD;
             anticoagulant effects.&#xD;
&#xD;
          -  Subject has known hypersensitivity to any of the ingredients&#xD;
&#xD;
          -  Subject is taking either pill, powder, or liquid forms of nutritional and/or health&#xD;
             food supplements within the past 4 weeks prior to visit&#xD;
&#xD;
          -  Subject unable to tolerate or unwilling to take the full dose of the nutritional study&#xD;
             formulas&#xD;
&#xD;
          -  Cystic fibrosis or any other chronic lung disease other than asthma.&#xD;
&#xD;
          -  Subject having gastroesophogeal reflux undergoing medical treatment&#xD;
&#xD;
          -  Significant medical illness other than asthma that could require oral corticosteroids&#xD;
             during the study.&#xD;
&#xD;
          -  Subject is receiving allergen hyposensitization therapy other than an established&#xD;
             maintenance regimen&#xD;
&#xD;
          -  Subject has received IV globulins or immunosuppressants.&#xD;
&#xD;
          -  Subject is known to be human immunodeficiency virus (HIV) positive.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  If of child bearing potential, failure to practice abstinence or use of an acceptable&#xD;
             birth control method.&#xD;
&#xD;
          -  Subject is morbidly obese&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stehen DeMichele, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2010</study_first_posted>
  <last_update_submitted>March 15, 2010</last_update_submitted>
  <last_update_submitted_qc>March 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bobbie Swearengin, Director</name_title>
    <organization>Abbott Nutrition</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

